Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity

International Archives of Allergy and Immunology

Volumn 144, Issue 4, 2007, Pages 287-295

  Adler Würtzen, Peter ^a   Lund, Lise ^a   Lund, Gitte ^a   Holm, Jens ^a   Millner, Anders ^a   Henmar, Helene ^a  

^a ALK ABELLÓ   (Denmark)

Author keywords

Allergoids; Allergy; Birch pollen; Histamine release; Immunoglobulin E; Immunotherapy; Intact allergens; Mouse immunizations; T cell proliferation

Indexed keywords

ALLERGEN; ALUMINUM POTASSIUM SULFATE; HISTAMINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY;

ALLERGENICITY; ALLERGY; ANTIBODY RESPONSE; ARTICLE; BASOPHIL; BIRCH; CHEMICAL MODIFICATION; CONTROLLED STUDY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; REDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADSORPTION; ALLERGENS; ALUM COMPOUNDS; ANIMALS; ANTIGENS, PLANT; BETULA; CELL LINE; GLUTARAL; HISTAMINE; HUMANS; HYPERSENSITIVITY; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PLANT EXTRACTS; PLANT PROTEINS; T-LYMPHOCYTES;

EID: 36248939777     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106317     Document Type: Article

References (25)

1. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558-562.
2. Durham SR, Walker SM, Varga EM, et al: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475.
3. Till SJ, Francis JN, Nouri-Aria K, Durham SR: Mechanisms of immunotherapy. J Allergy Clin Immunol 2004;113:1025-1034.
4. Jacobsen L: Immunotherapy for the prevention of allergic diseases. Clin Allergy Immunol 2004;18:529-540.
5. Moller C, Dreborg S, Ferdousi HA, et al: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-256.
6. Haugaard L, Dahl R, Jacobsen L: A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709-722.
7. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A: Efficacy and safety of pre-seasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005;60:801-807.
8. Bousquet J, Hejjaoui A, Skassa-Brociek W, et al: Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:591-598.
9. Marsh DG, Lichtenstein LM, Campbell DH: Studies on 'allergoids' prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 1970;18:705-722.
10. Ibarrola I, Sanz ML, Gamboa PM, et al: Biological characterization of glutaraldehydemodified Parietaria judaica pollen extracts. Clin Exp Allergy 2004;34:303-309.
11. Meriney DK, Kothari H, Chinoy P, Grieco MH: The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Ann Allergy 1986;56:34-38.
12. Klimek L, Dormann D, Jarman ER, Cromwell O, Riechelmann H, Reske-Kunz AB: Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999;29:1326-1335.
13. Kahlert H, Cromwell O, Fiebig H: Measurement of basophil-activating capacity of grass pollen allergens, allergoids and hypoallergenic recombinant derivatives by flow cytometry using anti-CD203c. Clin Exp Allergy 2003;33:1266-1272.
14. Gehlhar K, Peters M, Brockmann K, van Schijndel H, Bufe A: Characterization of modified allergen extracts by in vitro β-hexosaminidase release from rat basophils. Int Arch Allergy Immunol 2005;136:311-319.
15. Cirkovic T, Gavrovic-Jankulovic M, Prisic S, et al: The influence of a residual group in low-molecular-weight allergoids of Artemisia vulgaris pollen on their allergenicity, IgE- and IgG-binding properties. Allergy 2002;57:1013-1020.
16. Kalinski P, Lebre MC, Kramer D, De Jong EC, Van Schijndel JW, Kapsenberg ML: Analysis of the CD4+ T cell responses to house dust mite allergoid. Allergy 2003;58:648-656.
17. Dormann D, Ebner C, Jarman ER, Montermann E, Kraft D, Reske-Kunz AB: Responses of human birch pollen allergen-reactive T cells to chemically modified allergens (allergoids). Clin Exp Allergy 1998;28:1374-1383.
18. Kahler H, Stuwe H, Cromwell O, Fiebig H: Reactivity of T cells with grass pollen allergen extract and allergoid. Int Arch Allergy Immunol 1999;120:146-157.
19. Kahlert H, Grage-Griebenow E, Stuwe HT, Cromwell O, Fiebig H: T cell reactivity with allergoids: influence of the type of APC. J Immunol 2000;165:1807-1815.
20. Francis JN, Durham SR: Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004;4:543-548.
21. Larsen JN, Casals AB, From NB, Stroman P, Ipsen H: Characterization of recombinant bet vI, the major pollen allergen of Betula verrucosa (white birch), produced by fedbatch fermentation. Int Arch Allergy Immunol 1993;102:249-258.
22. Wurtzen PA, Nissen MH, Claesson MH: Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production. Scand J Immunol 2001;53:579-587.
23. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D: Neubewertung des Risikos von Test- und Therapieallergenen - Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2001;44:709-718.
24. Lund L, Henmar H, Würtzen PA, Lund G, Hjortskov N, Larsen JN: Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy. Clin Exp Allergy 2007;37:564-571.
25. HayGlass KT, Stefura W: Isotype-selective abrogation of established IgE responses. Clin Exp Immunol 1990;82:429-434.